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ABSTRACT:
Ewing sarcoma (ES) is an aggressive malignancy driven by an oncogenic fusion protein, 
EWS-FLI1. Neuropeptide Y (NPY), and two of its receptors, Y1R and Y5R are up-regulated by 
EWS-FLI1 and abundantly expressed in ES cells. Paradoxically, NPY acting via Y1R and Y5R 
stimulates ES cell death. Here, we demonstrate that these growth-inhibitory actions of NPY are 
counteracted by hypoxia, which converts the peptide to a growth-promoting factor. In ES cells, 
hypoxia induces another NPY receptor, Y2R, and increases expression of dipeptidyl peptidase 
IV (DPPIV), an enzyme that cleaves NPY to a shorter form, NPY3-36. This truncated peptide no 
longer binds to Y1R and, therefore, does not stimulate ES cell death. Instead, NPY3-36 acts as 
a selective Y2R/Y5R agonist. The hypoxia-induced increase in DPPIV activity is most evident in 
a population of ES cells with high aldehyde dehydrogenase (ALDH) activity, rich in cancer stem 
cells (CSCs). Consequently, NPY, acting via Y2R/Y5Rs, preferentially stimulates proliferation 
and migration of hypoxic ALDHhigh cells. Hypoxia also enhances the angiogenic potential of ES 
by inducing Y2Rs in endothelial cells and increasing the release of its ligand, NPY3-36, from ES 
cells. In summary, hypoxia acts as a molecular switch shifting NPY activity away from Y1R/Y5R-
mediated cell death and activating the Y2R/Y5R/DPPIV/NPY3-36 axis, which stimulates ES CSCs 
and promotes angiogenesis. Hypoxia-driven actions of the peptide such as these may contribute 
to ES progression. Due to the receptor-specific and multifaceted nature of NPY actions, these 
findings may inform novel therapeutic approaches to ES. 
INTRODUCTION
Ewing sarcoma (ES) is an aggressive malignancy 
affecting children and adolescents. The presence of 
metastases is the most adverse prognostic factor, with 
a 3-year event-free survival at 27% for patients with 
metastatic tumors [1]. This poor prognosis is associated 
with a frequent disease recurrence, suggesting that ES 
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tumorigenic potential is driven by chemotherapy-resistant, 
metastatic cancer stem cells (CSCs). A population of ES 
cells with elevated aldehyde dehydrogenase (ALDH) 
activity is particularly rich in CSCs, as shown by its 
increased tumorigenic potential and chemoresistance [2]. 
The fraction of CSCs often increases in hypoxia, 
leading to disease dissemination and resistance to therapy 
[3-5]. In ES, the hypoxia-driven increase in tumor cell 
malignancy has been demonstrated using experimental 
models, while clinically tumor ischemia associates with 
unfavorable disease phenotype [6-11]. However, the 
mechanisms governing these effects remain unknown. 
Malignant transformation of ES is driven by a 
chromosomal translocation resulting in fusion of the 
EWS gene with an ETS transcription factor, most often 
FLI1 [12]. Neuropeptide Y (NPY) and its Y1R and Y5R 
are among the transcriptional targets of EWS-FLI, highly 
expressed in ES tissues and cells [13-18]. However, 
microarray analysis revealed that mRNA of NPY’s Y2R, 
which is not detectable in ES cells in vitro, is elevated in 
tissues from metastatic ES [18, 19]. Given the high release 
of NPY from many ES cell lines [17], this expression 
pattern raises a question about the role of the endogenous 
peptide in these tumors. 
NPY is a 36 amino-acid neurotransmitter promoting 
proliferation and motility of various cells and regulating 
their differentiation [18, 20-26]. The peptide acts also 
as an angiogenic factor, stimulating endothelial cells 
(ECs) via their inducible Y2R [27]. Paradoxically, our 
data indicate that in ES, the EWS-FLI1-driven Y1R/
Y5R/NPY autocrine loop stimulates tumor cell death 
[17, 18]. However, we have also shown that this effect 
of endogenous NPY is mitigated by dipeptidyl peptidase 
IV (DPPIV) expressed in ES cells [17]. This enzyme 
cleaves full length NPY1-36 to a shorter form, NPY3-36, 
which does not bind to Y1Rs and is unable to stimulate 
ES cell death [17, 28]. Importantly, NPY3-36 preserves the 
ability to activate Y2Rs and Y5Rs and becomes a selective 
Y2R/Y5R agonist [28]. Thus, given the known role of 
Y2R in angiogenesis and elevated levels of its mRNA in 
metastatic ES tissues [19, 29-33], we sought to determine 
the function of the Y2R pathway in these tumors.
Hypoxia, known to enhance ES malignancy, also 
regulates the NPY system. As elements of the angiogenic 
pathway, NPY, its Y2R and DPPIV, which converts 
the peptide to a Y2R/Y5R agonist, are up-regulated in 
ischemic tissues [31, 34-36]. Therefore, we hypothesized 
that Y2Rs, which are undetectable in ES cells in vitro, 
are induced in the tumor microenvironment by hypoxia. 
Indeed, we have shown that hypoxic conditions promote 
NPY-induced angiogenic processes and activate the Y2R/
Y5R/DPPIV/NPY3-36 pathway in ES cells, changing the 
functions of the peptide from growth-inhibitory to growth-
promoting activities. The latter is particularly apparent in 
ALDHhigh CSCs, suggesting a potential role for NPY in 
promoting the malignant phenotype of hypoxic ES. These 
findings demonstrate for the first time the dynamic nature 
of NPY actions in ES and identify mechanisms by which 
tumor microenvironment converts the peptide to a growth-
promoting factor, specific for tumorigenic ES CSCs. 
Our study also reveals a novel mechanism governing a 
hypoxia-induced increase in ES malignancy. 
RESULTS
Y2R is expressed in endothelium and tumor cells 
from ES patient biopsies. 
Y2R mRNA is elevated in metastatic ES tumors 
[19]. To identify the specific cells expressing this receptor, 
tissue sections from 16 human ES tumors were stained 
with anti-Y2R antibody (Supplementary Table 1). Y2R 
was present in tumor cells and ECs (Fig. 1A). While ECs 
uniformly expressed Y2R, the tumors varied in percent of 
Y2R-positive ES cells, dichotomizing into two groups – 
low Y2R (0-10% of tumor cells stained) and high Y2R 
(40-100% of Y2R-positive ES cells) (Fig. 1A). High 
Y2R expression tended to correlate with worse survival 
at 23 months post diagnosis (50% and 100% for patients 
with high and low Y2R, respectively) (Supplementary 
Fig. 1, Supplementary Table 1). Due to the small sample 
size, however, the difference did not reach statistical 
significance (p = 0.09). 
In Y2R high tumors, intense Y2R staining was 
observed around blood lakes, which are perfused 
pseudovascular structures devoid of endothelial lining 
and therefore negative for endothelial marker, CD31 (Fig. 
1B-E). In ES, such pseudo-vessels are formed by hypoxic 
tumor cells [10]. Consequently, staining of serial tumor 
sections revealed that the entire area surrounding blood 
lakes was positive for a hypoxia marker, CAIX (Fig. 
1F) [37]. The cells with the highest CAIX expression 
were lining the lumens of blood lakes (Fig. 1C, F). The 
cells demarcating these pseudo-vessels were also highly 
positive for Y2R (Fig. 1C, E), suggesting preferential 
expression of this receptor in hypoxic ES cells. 
Hypoxia up-regulates the Y2R/Y5R/DPPIV/ 
NPY3-36 system in ES cells.
To determine whether expression of Y2R is 
induced by hypoxia, ES cells were cultured in 0.1% 
oxygen, which stabilized Hif-1α within 6h (Fig. 2A). 
This hypoxic response was associated with changes in 
the NPY system. Y2R mRNA expression was induced 
in all ES cell lines tested, while DPPIV mRNA was 
increased in three out of four cell lines (Fig. 2B). When 
analyzed as combined changes in all tested ES cell lines, 
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the increases in expression of Y2R and DPPIV were 
statistically significant, implicating these two genes as 
universal targets of hypoxia (Fig 2B). Levels of Y1R 
and Y5R mRNA remained unchanged. Consistently, in 
SK-ES1 cells, a model of NPY-rich ES [17], Western 
blot confirmed hypoxia-induced increases in Y2R and 
DPPIV protein levels, which was associated with elevated 
activity of the enzyme (Fig. 2C, D). Despite the lack of 
changes in Y5R mRNA, its protein levels were increased 
in hypoxic cells, while Y1R remained unchanged (Fig. 
2C). Altogether, these hypoxia-induced changes suggested 
activation of the Y2R/Y5R/DPPIV axis. 
Fig 1: Human ES express Y2Rs in endothelium and tumor cells. A. Y2R immunostaining in human ES tissue. ECs consistently 
express Y2R, while the percent of positive neoplastic cells varies between tumors. Based on the percent of Y2R-positive ES cells, tumors 
were categorized into low Y2R expression (0-10% of Y2R-positive ES cells) and high Y2R expression (40-100% of Y2R-positive cells). 
The representative images for both categories are shown. B, D-F. Serial sections of a tumor area with a typical blood vessel and blood lake 
stained with hematoxylin and eosin (H&E), anti-Y2R, anti-CD31 and anti-CAIX antibody. As shown by H&E staining (B), both structures 
are perfused, yet differentiated by positive and negative immunostaining for an endothelial marker, CD31, respectively (D). Tumor cells 
lining the blood lake lumen are positive for Y2R and a hypoxia marker, CAIX (E-F). C. The cellular populations within tumor tissues 
were divided into three categories: ES cells distant from vasculature (tumor cells within tumor parenchyma, not directly surrounding 
tumor vasculature or pseudo-vessels), endothelium (ECs within blood vessel lumen) and ES cells lining blood lakes (1-2 cellular layers 
demarcating blood lake lumen). Intensities of CD31, Y2R and CAIX immunoreactivity in particular cellular fractions were quantified and 
compared to the ES cells within tumor parenchyma. T- tumor cells; ECs – endothelial cells; BL – blood lake; V – blood vessel; red arrows 
indicate tumor cells lining lumen of blood lake
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Y2R and DPPIV are expressed in hypoxic areas 
of ES tissue.
 To confirm the hypoxia-induced changes in the NPY 
system in vivo, we used an orthotopic ES xenograft model. 
Mice bearing SK-ES1 tumors were injected with a hypoxia 
probe, pimonidazole, and the tumors were harvested 24h 
later. Staining of tumor tissues with anti-pimonidazole 
antibody exhibited a characteristic pattern of hypoxic 
areas located near the necrotic regions, surrounding 
blood vessels at a distance of approximately 100 µm 
(Fig. 2E). Double-staining with anti-pimonidazole and 
anti-Y2R or anti-DPPIV antibody revealed accumulation 
of both proteins in hypoxic areas (Fig. 2F), supporting 
observations in human ES tissues (Fig. 1B-F). 
Fig 2: Hypoxia up-regulates the Y2R/Y5R/DPPIV system in ES cells. A. Western blot analysis of Hif-1α expression in SK-
ES1 cells cultured in 0.1% oxygen. B. mRNA levels of NPY receptors and DPPIV measured by real-time RT-PCR in four ES cell lines 
exposed to 0.1% oxygen for 12-24h. To identify genes universally elevated in hypoxic ES cells, the statistical analysis was performed on 
combined changes in all ES cell lines (dashed box). C. Western blot analysis of NPY receptor and DPPIV protein levels in cell membrane 
fractions from SK-ES1 cells cultured in normoxia or hypoxia for 24h. CAIX and flotillin-1 served as a hypoxia marker and loading 
control, respectively. Protein levels from three independent experiments were quantified by densitometry. D. Selective DPPIV activity 
was measured calorimetrically in SK-ES1 cells cultured for 24h in normoxia or hypoxia. E. SK-ES1 orthotopic xenografts were treated 
in vivo with an extrinsic hypoxia marker, pimonidazole, for 24h. Tumor sections were stained with H&E and anti-pimonidazole antibody. 
F. Double staining of the above SK-ES1 orthotopic xenografts with anti-pimonidazole (nickel) and anti-Y2R or anti-DPPIV (brown) 
antibodies. V – blood vessel; P- pimonidazole; N - necrosis.
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Hypoxia prevents the Y1R/Y5R-mediated cell 
death in ES cells and triggers a stimulatory effect 
of NPY on their anchorage-independent growth.
 NPY stimulates ES cell death via the Y1R/Y5R 
pathway, while DPPIV counteracts this process by 
inactivating the peptide at Y1Rs [17, 18]. Since hypoxia 
up-regulated DPPIV, we sought to determine if this could 
prevent NPY-induced cell death. In normoxia, the full-
length NPY, but not the product of DPPIV cleavage, NPY3-
36, decreased the number of SK-ES1 soft agar colonies 
(Fig. 3A, B). This effect was not observed in hypoxia, 
the condition favoring DPPIV (Fig. 3A, B). Instead, 
hypoxia alone increased the size of SK-ES1 colonies, 
while both NPY and NPY3-36 administered under hypoxic 
conditions further augmented this effect (Fig. 3A, C). 
Since anchorage-independent growth depends on CSCs, 
and NPY3-36 selectively activates Y2R and Y5R, these 
results suggested a Y2R/Y5R-dependent increase in ES 
CSC proliferation. 
Y2R/Y5R/DPPIV system is preferentially 
activated in hypoxic ES CSCs. 
The results of soft agar assay suggested that hypoxia-
induced changes in the NPY system affect CSCs. Thus, in 
the subsequent experiments, we focused on ES cells with 
high ALDH activity, which have been shown to be rich 
in CSCs [2]. Culture under hypoxic conditions increased 
the number of SK-ES1 cells with elevated ALDH activity 
(Fig. 4A), suggesting hypoxia-driven enrichment in CSCs. 
To assess expression of the NPY system in ES CSC, SK-
ES1 cells were sorted by flow cytometry into ALDHhigh 
and ALDHlow cells (Supplementary Fig. 2). This approach 
allowed for testing two cell populations with maximal 
difference in ALDH activity. The efficiency of sorting 
was confirmed by elevated expression of one of the main 
forms of ALDH, ALDH1, and a stem cell marker, Oct-
4, in ALDHhigh cells (Fig. 4B). Western blot analysis of 
ALDHlow and ALDHhigh cells cultured under normoxic 
and hypoxic conditions revealed hypoxia-induced up-
regulation of Y2R protein in both cell fractions (Fig. 4C). 
However, in normoxia and hypoxia, expression of DPPIV 
was higher in ALDHhigh cells, as compared to ALDHlow 
cells. Consequently, hypoxic CSCs had the highest DPPIV 
protein and activity levels (Fig. 4C, D). 
NPY stimulates proliferation and migration of 
hypoxic ES CSCs.
Having established hypoxia-induced changes in 
NPY system expression, we sought to determine their 
functional consequences. To this end, SK-ES1 cells were 
Fig 3: Hypoxia prevents NPY-driven cell death and triggers its stimulatory effect on anchorage-independent growth. A. 
SK-ES1 cells were plated on soft agar in the presence or absence of full-length NPY or NPY3-36 (10-7M). Plates were incubated in normoxia 
or hypoxia for 14 days. Pictures of the representative wells for each treatment group are shown under low and high magnification. B. 
Average number of soft agar colonies per well in each experimental group. C. Average colony size under normoxic and hypoxic conditions
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sorted into a population of ALDHhigh and ALDHlow cells 
as above. Although there were no significant differences 
in basal levels of the proliferation and migration between 
these cell fractions (data not shown), the cells varied in 
their responses to NPY.
In normoxia, NPY had no significant effect on the 
proliferation of ALDHhigh and ALDHlow SK-ES1 cells 
(Fig. 5A). However, in hypoxia, the peptide selectively 
stimulated proliferation of ALDHhigh cells. This effect 
of NPY in hypoxic ALDHhigh cells was mimicked by 
Y2R/Y5R-specific treatment - the full-length NPY in 
the presence of Y1R antagonist or a Y2R/Y5R selective 
agonist, NPY3-36 (Fig. 5A). Consequently, both Y2R and 
Y5R antagonists reduced the mitogenic effect of NPY in 
hypoxic ALDHhigh cells (Fig. 5A). 
Similar to its proliferative actions, full-length 
NPY stimulated migration preferentially in hypoxic 
ADLHhigh SK-ES1 cells (Fig. 5B). Treatment with NPY 
in the presence of Y1R antagonist or with NPY3-36 further 
enhanced the NPY-induced SK-ES1 cell migration 
in hypoxia. This Y2R/Y5R-specific treatment also 
moderately increased migration of normoxic ALDHhigh and 
Fig 4: The Y2R/Y5R/DPPIV system is preferentially activated in ALDHhigh ES CSCs. A. SK-ES1 cells were cultured in 
normoxia or hypoxia for 24h, stained with Aldefluor, and ALDH activity was measured by FACS. The non-stained cells or the cells 
incubated with Aldefluor in the presence of ALDH inhibitor, DEAB, served as negative controls. B. SK-ES1 cells were stained with 
Aldefluor and FACS-sorted based on the ALDH activity into ALDHhigh (upper 8% of cells) and ALDHlow (lower 10% of cells) cells. The 
levels of ALDH-1 protein and stem cell marker, Oct-4, were compared by Western blot in soluble protein fractions of ALDHhigh and 
ALDHlow cells, to confirm the efficiency of cell sorting. C. ALDHhigh and ALDHlow cells were cultured for 24h in normoxia and hypoxia. 
Protein levels of Y2Rs and DPPIV were detected in cell membrane fractions isolated from these cells by Western blot. Flotillin-1 served as 
a loading control. Protein levels from 4 independent experiments were quantified by densitometry. D. DPPIV activity was measured in the 
above cell membrane fractions via luminescent method. 
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ALDHlow cells (Fig. 5B). The effect of NPY in hypoxic 
ALDHhigh cells was blocked by the combination of Y2R 
and Y5R antagonist (Fig. 5B). Altogether, these results 
demonstrate the Y2R/Y5R-mediated mitogenic and pro-
migratory activity of NPY, which is triggered by hypoxia 
favoring the Y2R/Y5R/DPPIV system in ES CSCs.
Hypoxia enhances the ability of ES cells to 
stimulate angiogenesis via release of NPY.
NPY is an angiogenic factor acting via its Y2R, 
the expression of which is induced in ECs by hypoxia 
or exposure to NPY [27, 31]. The peptide has been 
previously implicated in the vascularization of ES tumors 
[18]. To determine if its angiogenic effect is enhanced by 
hypoxia, we used two ES cell lines varying in NPY release 
[17]. In SK-ES1 cells, which constitutively express high 
levels of NPY, 24h culture in hypoxia further increased 
NPY synthesis and release (Fig. 6A). No increase in NPY 
expression was observed in ES925 cells, which do not 
secrete the peptide under basal conditions (Fig. 6A). 
To determine functional consequences of these 
changes, we tested the effect of conditioned media from 
normoxic and hypoxic ES cells on HMVEC proliferation. 
The proliferative effects of conditioned media from 
normoxic SK-ES1 and ES925 were comparable and 
not dependent on NPY, since Y2R antagonist did not 
significantly decrease them (Fig. 6B). Conditioned 
media from hypoxic SK-ES1 cells exerted a higher 
proliferative effect, as compared to the media from 
normoxic cells (Fig. 6B). This hypoxia-induced increase 
in HMVEC proliferation was blocked by Y2R, proving its 
dependency on NPY. No statistically significant increase 
in proliferative activity of conditioned media from hypoxic 
ES925 cells was observed, consistent with the lack of NPY 
release from these cells (Fig. 6A, B). 
Fig 5: NPY stimulates proliferation and migration of hypoxic ALDHhigh ES CSCs via the Y2R/Y5R pathway. A. ALDHhigh 
and ALDHlow cells were pre-incubated for 6h in normoxia or hypoxia and then treated under the same conditions with the desired NPY 
receptor agonists (10-7M) or antagonists (10-6M) for 12h. Cells were subsequently pulsed with 10µM EdU, and proliferation was measured 
as a percent of EdU positive cells. B. ALDHhigh and ALDHlow cells were plated into BD FluoroBlok plates, treated as above for 18h and 
stained with Calcein AM. Cell migration was assessed based on fluorescence measured from the bottom of the plate.
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Hypoxia sensitizes ECs to NPY released from ES 
cells. 
Having established the hypoxia-induced increase 
in NPY release from ES cells, we sought to determine 
if its angiogenic activity can be augmented by parallel 
changes in ECs. HMVECs were cultured in 0.1% oxygen, 
which up-regulated Hif-1α within 6h (Fig. 7A). After 
24h, hypoxia induced Y2R, which was not detectable in 
normoxic HMVECs (Fig. 7A). Simultaneously, hypoxia 
increased DPPIV protein levels (Fig. 7A) and augmented 
its activity up to 140% of the normoxic control (data 
not shown). This hypoxia-induced activation of the 
Y2R/DPPIV system sensitized HMVECs to NPY. The 
mitogenic activity of the peptide was elevated in hypoxic 
HMVECs, as compared to the normoxic cells (Fig. 7B). 
In normoxia and hypoxia, NPY effects were blocked by 
Y2R antagonist. Similarly, NPY-rich SK-ES1 conditioned 
media exerted enhanced proliferative activity in hypoxic 
HMVECs, as compared to normoxic cells (Fig. 7C). 
Y2R antagonist blocked this effect, thereby confirming 
its dependency on activation of the Y2R/DPPIV system 
in ECs. The proliferative activity of ES925 conditioned 
media, which lacks NPY, was also higher in hypoxic 
HMVECs (Fig. 7C). However, Y2R antagonist did not 
block this increase.  
Y2R antagonist reduces vascularization of ES 
xenografts.
Our observations in vitro suggested that the 
angiogenic activity of NPY in ES is induced in tumor 
microenvironment by hypoxia. To confirm this, SK-
ES1 subcutaneous xenografts were treated with Y2R 
antagonist. This blockage of Y2R resulted in significant 
decrease in tumor vascularization, as measured by area of 
CD31-positive endothelial cells (Fig. 8A, B). This effect 
was associated with reduced mRNA levels of mouse 
vascular endothelial growth factor receptor 2 (VEGFR2) 
(Fig. 8C). Altogether, these results confirm the role of 
NPY and its Y2R in ES vascularization.  
DISCUSSION
Growing evidence indicates a role of hypoxia 
in ES progression. In ES patients, tumor ischemia is 
associated with an unfavorable metastatic pattern, while 
its absence correlates with better prognosis [11]. In vitro, 
hypoxia up-regulates EWS-FLI1 protein and modifies its 
transcriptional profile, promoting genes involved in tumor 
progression [6]. Hypoxic ES cells exhibit an enhanced 
anchorage-independent growth, invasiveness, and 
resistance to apoptosis induced by exogenous factors [6-
9, 38]. However, the mechanisms of these effects remain 
unclear. In fact, some data indicate no hypoxia-induced 
changes in ES cell proliferation, but rather an increase in 
apoptosis when the cells are assayed as a whole population 
in adherent culture [6, 7]. Thus, such a hypoxia-induced 
increase in tumor malignancy may be driven by specific 
changes in CSCs.
CSCs are resistant to low oxygen and their fraction 
increases in hypoxia-treated tumor cells [3-5]. In our 
study, hypoxic conditions increased the population of 
ES cells with high ALDH activity, which are rich in 
tumorigenic CSCs. We propose that this enrichment in 
ES CSCs in combination with activation of the Y2R/Y5R/
DPPIV/NPY3-36 system in these cells is one of the driving 
mechanisms governing the hypoxia-driven increase in ES 
malignancy. 
NPY, and its Y1R and Y5R are transcriptional 
targets of EWS-FLI1 up-regulated in ES [13, 14]. 
Paradoxically, we have previously shown that this Y1R/
Y5R/NPY autocrine loop stimulates ES cell death [17, 
18]. However, mRNA of another NPY receptor, Y2R, is 
Fig 6: Hypoxia augments the ability of ES cells to 
trigger angiogenesis via release of NPY. A. SK-ES1 and 
ES925 cells were cultured in normoxia or hypoxia for 24h. 
NPY mRNA in ES cells was measured by real-time RT-PCR, 
while ELISA was used to measure NPY concentrations in their 
conditioned media. B. HMVEC cells were growth-arrested and 
treated with conditioned media from hypoxic and normoxic ES 
cells. HMVEC proliferation was measured by [3H]thymidine 
uptake
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up-regulated in metastatic ES tissues [19]. Since Y2R is 
not detectable in cultured ES cells [18], the goal of our 
study was to determine its localization and function in 
ES. Y2R was present in ECs, but also in tumor cells, and 
observed to accumulate in hypoxic areas. Consistently, we 
have shown that Y2R expression is induced in ES cells by 
hypoxia. This effect was associated with increases in NPY 
release, Y5R protein levels, and in expression of DPPIV, 
an enzyme converting the peptide to a selective Y2R/Y5R 
agonist. These changes suggested an overall hypoxia-
induced activation of the Y2R/Y5R/DPPIV/NPY3-36 axis. 
Similar up-regulation of the NPY system was reported in 
ischemic tissues, while DPPIV was elevated in various 
hypoxic tumor cells [31, 34-36]. 
ES cells are rich in Y1R, which is expressed in 
response to EWS-FLI1 [13-16, 18]. However, in hypoxia, 
Y1R expression did not change, while levels of Y2R and 
Y5R increased, altering the NPY receptor ratio. Moreover, 
increased DPPIV activity, such as that observed in hypoxic 
ES cells, alters the form of released NPY to NPY3-36, a 
selective Y2R/Y5R agonist [17]. Altogether, these changes 
prevent binding of NPY to Y1Rs and block ES cell death 
mediated by the Y1R/Y5R/NPY1-36 pathway. Furthermore, 
DPPIV-induced cleavage of NPY enables the activation 
of moderately expressed Y2Rs and Y5Rs in the presence 
of abundant Y1Rs. We have shown that while Y2Rs 
are induced in both ALDHhigh and ALDHlow, DPPIV is 
preferentially up-regulated in ALDHhigh cells. Our results 
are in agreement with reports of DPPIV serving as a 
marker of metastatic CSCs in other tumors [39]. 
Consistent with preferential DPPIV activation 
in CSCs, NPY stimulated the proliferation of hypoxic 
ALDHhigh cells, but not ALDHlow cells. The fact that either 
Y2R or Y5R alone blocked this effect suggested that 
activation of both receptors is required to trigger it. The 
selective mitogenic activity of NPY in ALDHhigh cells 
is consistent with reports indicating differential effects 
of hypoxia and NPY on ES cells, depending on culture 
conditions. While both factors increase the size of CSC-
dependent soft agar colonies, they have no effect on the 
proliferation of non-sorted, adherent cells, comprised 
mostly of non-CSCs [6, 7, 18]. 
As observed for its proliferative effect, full-length 
NPY stimulated migration only in hypoxic ALDHhigh cells. 
However, treatment with NPY in the presence of Y1R 
antagonist or with NPY3-36 alone augmented this effect 
and moderately increased cell migration in normoxic 
ALDHhigh and ALDHlow cells. These observations suggest 
that in normoxia, selective activation of Y5Rs is sufficient 
to stimulate ES cell migration, while hypoxia-induced 
expression of Y2Rs further augments this process. 
Consequently, both Y2R and Y5R antagonists were 
required to block the pro-migratory effects of NPY in 
Fig 8: Y2R antagonist impairs vascularization of ES 
xenografts. A. Representative images of immunostaining for 
endothelial marker, CD31, in SK-ES1 subcutaneous xenografts 
treated with placebo or Y2R antagonist (10-6M). B. Tumor 
vascularization of control and Y2R antagonist-treated SK-ES1 
xenografts measured by area of CD31 staining. C. mRNA levels 
of mouse VEGFR2 measured in SK-ES1 xenografts by real-time 
RT-PCR
Fig 7: Hypoxia sensitizes ECs to NPY. A. HMVECs were 
cultured in 0.1% oxygen. Hif-1α protein was detected in soluble 
protein fractions by Western blot at desired time points, while 
Y2R and DPPIV proteins were measured in cell membrane 
preparations upon 24h incubation in normoxia or hypoxia. B. 
HMVECs were growth arrested for 24h under normoxia or 
hypoxia and treated for the following 24h with NPY (10-7M) 
with or without Y2R antagonist (10-6M) at the respective oxygen 
concentrations. Proliferation was measured by [3H]thymidine 
uptake. C. HMVECs were pretreated as above, stimulated with 
conditioned media from ES cells cultured under basal conditions, 
and incubated in normoxia or hypoxia for the following 24h. 
Proliferation was measured as above.
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hypoxic ALDHhigh cells, suggesting that independent 
activation of one of these receptors promotes cell 
migration. Altogether, our data indicate that hypoxia-
induced changes in NPY functions are particularly 
apparent in a CSC-rich ALDHhigh cells. These changes 
may contribute to the increase in ES metastatic properties, 
albeit without an effect on the primary tumor growth that 
is dependent mostly on non-CSCs. Future studies with 
animal models will explore this hypothesis. 
The angiogenic activity of NPY depends on 
Y2R [30]. In hypoxic NPY-rich ES cells, simultaneous 
increases in NPY and DPPIV expression led to elevated 
release of the peptide, presumably as a Y2R/Y5R-selective 
agonist, NPY3-36. This, in turn, increased the angiogenic 
activity of ES conditioned media. This stimulatory effect 
was further enhanced by increases in Y2R and DPPIV 
expression in hypoxic ECs, which sensitized them to 
NPY’s proliferative effect. Consequently, Y2R antagonist 
significantly reduced vascularization of NPY-rich ES 
xenografts. Y2R expression in ECs within human ES 
tissues supported the clinical relevance of these findings.
The elevated responsiveness of hypoxic ECs to 
ES conditioned media lacking NPY implicated a role 
for other ES-derived angiogenic factors, such as VEGF 
[40]. Importantly, the NPY and VEGF angiogenic 
systems are interdependent, with NPY serving as an 
upstream factor [31, 41]. Consistently, Y2R antagonist 
decreased expression of VEGFR2 in NPY-rich SK-ES1 
xenografts, suggesting that VEGF pathway activation 
is NPY-dependent. Importantly, SK-ES1 cells have low 
basal VEGF levels and lack mechanisms that mediate 
its hypoxia-induced up-regulation in other ES cells [40]. 
Therefore, in the subset of such VEGF-insufficient tumors, 
hypoxia-induced activation of the NPY system is essential 
to maintain tumor vascularization by direct stimulation of 
ECs and up-regulation of VEGF system. 
NPY receptor patterns in ES and ECs are similar, 
with constitutively expressed Y1R and inducible Y2R 
[17, 27]. Consequently, in both cases, DPPIV-induced 
NPY cleavage is essential to enable activation of Y2Rs, 
which are expressed at lower levels than abundant Y1Rs. 
These observations suggest a potential for multifunctional 
therapies for ES. Since the same Y2R/Y5R/DPPIV/NPY3-
36 system is responsible for hypoxia-induced proliferative 
and pro-migratory effects of NPY in ECs and ES CSCs, 
blocking this pathway in vivo may target both metastatic 
and angiogenic properties of the tumors. This has been 
shown in neuroblastoma, where Y2R antagonist reduced 
xenograft growth via inhibition of tumor cell proliferation 
and vascularization [27].
In addition to the typical vasculature, ES tumors 
are known to form pseudo-vessels, also called blood 
lakes, which augment blood flow to the tumor tissue. 
An increased presence of these structures is associated 
with poor prognosis in ES patients [42]. The formation 
of pseudo-vessels is driven by hypoxia [10]. Consistently, 
the tumor cells surrounding them are positive for hypoxia 
markers, as well as Y2R. These observations warrant 
further investigation as to the potential role for Y2R and 
NPY in vascular mimicry. 
Altogether, our results revealed the dynamic nature 
of NPY actions in ES and critical role of the tumor 
microenvironment in their regulation. The net effect of 
endogenous NPY on ES depends on the balance between 
Fig 9: Model of NPY actions in ES. In normoxia, NPY is released as a full-length peptide and stimulates Y1/Y5R-mediated ES cell 
death. Hypoxia increases expression of Y2R, Y5R and DPPIV in ES CSCs. These changes lead to cleavage of NPY and selective activation 
of Y2R/Y5Rs, which promotes proliferation and migration of these tumorigenic cells. NPY3-36, a product of DPPIV cleavage, stimulates also 
Y2Rs expressed in hypoxic ECs and promotes angiogenesis. Altogether, these hypoxia-induced actions may promote tumor progression
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Y1R/Y5R/NPY1-36 growth-inhibitory effects on the entire 
population of ES cells and Y2R/Y5R/DPPIV/NPY3-36 
proliferative and pro-migratory effects on ES CSCs and 
ECs (Fig. 9). Hypoxia shifts this balance toward growth-
promoting processes by preventing activation of Y1Rs 
and promoting the Y2R/Y5R pathway. Further studies are 
required to determine the impact of these changes in the 
NPY system on ES progression and metastases. 
Despite the complexity of NPY functions in ES, 
the receptor specificity of its actions and potential for 
multifaceted therapeutic effects make the peptide and 
its receptors attractive targets in ES treatment. We have 
shown that exogenous NPY inhibits ES xenograft growth 
via Y1R/Y5R-mediated cell death [17, 18]. Thus, receptor 
specific interventions activating the Y1R/Y5R pathway, 
inhibiting Y2R/Y5Rs, and/or targeting DPPIV may 
provide new therapeutic opportunities for ES patients. 
Recently, a variety of selective NPY receptor agonists 
and antagonists have been developed. This includes Y1R/
Y5R selective agonists and various Y2R antagonists 
[43]. Some of them, such as DPP inhibitors and Y5R 
antagonist are already being used in clinical practice or 
trials for other disorders [44-46]. Importantly, however, 
our previous studies indicate that prolonged treatment of 
ES xenografts with DPP inhibitors results in increased 
DPPIV expression, which overcomes their effects [17]. 
While this could possibly be circumvented by changes in 
drug regimen or its potency, targeting NPY receptors may 
be a better therapeutic strategy. This approach is also more 
specific, given the high range of known DPPIV substrates. 
In summary, we have shown for the first time 
fundamental changes that can occur in the NPY/
DPPIV system within the tumor microenvironment and 
their functional consequences. Our findings highlight 
the importance of assessing NPY functions in tissue 
environment, uncover its novel role in cancer stem cells 
and reveal mechanisms governing a hypoxia-induced 
increase in tumor malignancy. Although our study 
focuses on ES, hypoxia-induced activation of the Y2R/
Y5R/ DPPIV/NPY3-36 axis may be applicable to other 
tumors rich in NPY and its receptors. A similar pattern 
of NPY receptor expression and its effect on tumor cell 
proliferation and migration has been reported in breast 
cancer [21, 23]. The evidence of a role for both NPY and 
DPPIV in a variety of other tumors is also growing [18, 
27, 47-49]. Thus, understanding the NPY system may 
direct new therapeutic opportunities for patients with 
metastatic ES, thus far lacking an effective treatment, as 
well as those with other malignancies. 
METHODS
Materials: 
NPY and NPY3-36 were purchased from Bachem 
(San Carlos, CA); Y1R antagonist, BIBP 3226, from 
Sigma (St. Louis, MO); Y5R antagonist, CGP71683, 
and Y2R antagonist, BIIE0246, from Tocris (Ellisville, 
MO). DPPIV inhibitor, Sitagliptin, was a gift from Dr. 
Bachovchin (Tufts University, Boston, MA). 
Human tissue sections from 16 ES archival 
paraffin embedded samples were collected from multiple 
institutions in Poland by one of the co-authors (EIS) in 
compliance with institutional ethical regulations. Use of 
these samples was approved by Georgetown University 
Institutional Review Board.
ES xenografts:
For the orthotopic xenografts, SK-ES1 cells were 
injected into gastrocnemius muscles of SCID/bg mice 
[50]. Once tumors reached 1cm3, mice were injected 
intraperitoneally with a hypoxia probe, pimonidazole 
(HPI, Burlington, MA), 1.5mg/mouse, and tumors were 
harvested 24h later. For the subcutaneous xenografts, 
SK-ES1 cells were injected into nude mice and treated 
daily with local injections of Y2R antagonist (10-6M) [17, 
27]. Treatment was initiated when the tumors reached a 
volume of approximately 100mm3, and the experiment 
was terminated 2 weeks later. Tumor vascularization was 
quantified by immunohistochemistry, as area of positive 
staining for endothelial marker, CD31, while expression 
of mouse vascular endothelial growth factor receptor 2 
(VEGFR2) was measured by real-time RT-PCR.
Immunohistochemistry
Immunohistochemistry was performed using 
the following antibodies: rabbit polyclonal anti-
Y2R (Neuromics, Edina, MN), anti-CD26 (Novus 
Biologicals, LLC, Littleton, CO), anti-pimonidazole 
(HydroxyprobeTM-1 kit) (HPI, Inc. Burlington, MA), anti-
carbonic anhydrase IX (CAIX) and anti-mouse CD31 
(Abcam, Cambridge, MA) and mouse monoclonal anti-
human CD31 (DAKO, Carpinteria, CA). Staining intensity 
was quantified using Metamorph software. 
Cell culture: 
Human ES cells were obtained and cultured as 
previously reported [17]. Human dermal microvascular 
endothelial cells (HMVEC) purchased from Lonza (Basel, 
Switzerland) were cultured according to the supplier’s 
recommendation. Hypoxia was created in a chamber 
containing 0.1% O2, 95% N2 and 5% CO2.
Real time RT-PCR and NPY ELISA were performed 
as previously described [17, 18].
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Aldefluor assay and cell sorting: 
ES cells were stained using ALDEFLUOR 
kit (Stemcell Technologies, Vancouver, Canada). 
Fluorescence-activated cell sorting (FACS) was performed 
on FACSAria (BD, Franklin Lakes, NJ) utilizing 
FACSDiva and FCS Express 4 softwares (DeNovo 
Software, Los Angeles, CA). Cells were sorted into 
ALDHhigh (upper 8%) and ALDHlow cells (lower 10%), 
cultured for no longer than 24h in normoxia or hypoxia, 
and assayed as desired.  ALDH activity in normoxia and 
hypoxia was measured by FACS upon 24h culture.  
Cell membrane isolation and Western blot: 
Cell lysates were fractionated into membrane and 
soluble proteins, as previously described [51]. Western 
blot was performed using the following antibodies: rabbit 
polyclonal anti-Y1R (gift from Dr. Urban, University 
of Chicago), anti-DPPIV and anti-CAIX (Abcam, 
Cambridge, MA), anti-flotilllin-1 (Sigma, St. Louis, 
MO) and anti-hypoxia-inducible factor 1α (Hif-1α) (Cell 
Signaling Technologies, Danvers, MA),  goat polyclonal 
anti-Npy2r (My Biosource, Camarillo, CA) and anti-Y5R 
(Everest Biotech, Ramona, CA) and mouse monoclonal 
anti-ALDH1 (BD Biosciences, San Jose, CA), anti-Oct-4 
(Santa Cruz Biotechnology, Santa Cruz, CA) and anti-β-
actin (Sigma, St. Louis, MO). 
DPP activity from unsorted cells was measured 
calorimetrically, as previously described [17], while for 
sorted ES cells DPPIV-Glo™ Protease Assay (Promega, 
Madison, WI) was used. DPPIV activity was calculated 
as a fraction of DPP activity blocked by its selective 
inhibitor, Sitagliptin (10-5M) [17].
Colony formation on soft agar was performed as 
previously described [17]. Cells were treated with NPY 
or NPY3-36 (10-7M) and incubated in normoxia or hypoxia 
for 14 days. 
ES cell proliferation was measured using Click-
iT® EdU cell proliferation assay (Life Technologies, 
Grand Island, NY). ALDHhigh and ALDHlow ES cells 
were pre-incubated in normoxia or hypoxia for 6h and 
treated with NPY (10-7M) +/- receptor antagonists (10-
6M) or with NPY3-36 (10-7M) for 12h. Cells were pulsed 
with EdU, fixed and fluorescently labeled according to the 
manufacturer’s procedure. Proliferation was measured as 
a percent of EdU-positive cells.  
ES cell migration: 
ALDHhigh and ALDHlow cells were plated onto BD 
FluoroBlok™ 96-well plates (BD Biosciences, San Jose, 
CA), pre-incubated for 6h in hypoxia or normoxia and 
treated as above for 18h. Cells were stained with Calcein 
AM and fluorescence was measured from the bottom of 
the plate.
HMVEC proliferation:
ES cells were grown in HMVEC culture media, 
which was collected 24h later. HMVECs were plated onto 
96-well plates, growth-arrested for 24h, and then treated 
for 24h with NPY (10-8M) or ES-conditioned media, +/- 
Y2R antagonist (10-6M). Proliferation was measured using 
[3H] thymidine [18].
Statistical analysis:
Statistical analysis was performed using SigmaStat® 
and GraphPad softwares.  One-way repeated measure 
ANOVA with post-hoc t-test (P<0.05) using Dunnett’s 
method was used for data comparison and analysis.  All 
experiments were repeated at least three times. Data is 
presented as mean ± standard errors.
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